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Pharmacoethnicity in Paclitaxel-Induced Sensory
Peripheral Neuropathy
Masaaki Komatsu1, Heather E.Wheeler1, Suyoun Chung1,2, Siew-Kee Low3,4,
Claudia Wing1, Shannon M. Delaney1, Lidija K. Gorsic1, Atsushi Takahashi3,
Michiaki Kubo5, Deanna L. Kroetz6,Wei Zhang7, Yusuke Nakamura1,4, and
M. Eileen Dolan1
Abstract
Purpose: Paclitaxel is used worldwide in the treatment of
breast, lung, ovarian, and other cancers. Sensory peripheral
neuropathy is an associated adverse effect that cannot be pre-
dicted, prevented, or mitigated. To better understand the con-
tribution of germline genetic variation to paclitaxel-induced
peripheral neuropathy, we undertook an integrative approach
that combines genome-wide association study (GWAS) data
generated from HapMap lymphoblastoid cell lines (LCL) and
Asian patients.
Methods: GWAS was performed with paclitaxel-induced
cytotoxicity generated in 363 LCLs and with paclitaxel-
induced neuropathy from 145 Asian patients. A gene-based
approach was used to identify overlapping genes and com-
pare with a European clinical cohort of paclitaxel-induced
neuropathy. Neurons derived from human-induced pluripo-
tent stem cells were used for functional validation of candi-
date genes.
Results: SNPs near AIPL1 were signiﬁcantly associated with
paclitaxel-induced cytotoxicity inAsian LCLs (P < 106).Decreased
expression of AIPL1 resulted in decreased sensitivity of neurons
to paclitaxel by inducing neurite morphologic changes as measur-
ed by increased relative total outgrowth, number of processes
and mean process length. Using a gene-based analysis, there were
32 genes that overlapped between Asian LCL cytotoxicity and
Asian patient neuropathy (P < 0.05), including BCR. Upon BCR
knockdown, there was an increase in neuronal sensitivity to pacli-
taxel as measured by neurite morphologic characteristics.
Conclusions: We identiﬁed genetic variants associated with
Asian paclitaxel-induced cytotoxicity and functionally validat-
ed the AIPL1 and BCR in a neuronal cell model. Furthermore,
the integrative pharmacogenomics approach of LCL/patient
GWAS may help prioritize target genes associated with che-
motherapeutic-induced peripheral neuropathy. Clin Cancer Res;
21(19); 4337–46. 2015 AACR.
Introduction
Paclitaxel, a microtubule-stabilizing agent that binds tubulin
anddisrupts cell division, represents standard of care for common
cancers, including breast, lung, and ovarian cancer (1). Unfortu-
nately, about 20% to 30% of patients treated with paclitaxel
experience clinically relevant sensory peripheral neuropathy
(2, 3). Furthermore, there is substantial interpatient variability
in time to symptom onset, time to peak symptoms, severity of
peak symptoms, and reversibility (4, 5). Patients experiencing
moderate to severe chemotherapy-induced peripheral neuropa-
thy (CIPN) report a reduced quality of life, chronic discomfort,
and disruption of physical abilities for general life activities that
can be temporary or permanent (6). CIPN causes a signiﬁcant
symptom burden because many patients that undergo adjuvant
treatment are long-term survivors. Moreover, CIPN can lead
to dose reduction of the chemotherapeutic agent or possible
cessation of treatment (7). This may have an adverse impact on
cancer treatment and disease outcomes, particularly in the adju-
vant setting.
There are few effective methods in clinical practice for man-
aging peripheral neuropathy. ASCO recommendations, recently
published (7) and based on a systematic evaluation of 48
randomized controlled trials, concluded that there are no agents
recommended for the prevention of CIPN and supported a
moderate recommendation of duloxetine for pain associated
with CIPN (8). Physical therapy, acupuncture, massage, and
medications such as steroids, antiepileptics, antidepressants,
and opioids for pain management are often attempted. Unfortu-
nately, the extent to which these interventions improve symp-
toms is limited and some of these interventions carry side
effects of their own (7). An improved understanding of the
genetic variants and genes contributing to paclitaxel induced
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neuropathy will assist in the development of future neuropro-
tective agents and in the design of novel therapies with
improved toxicity proﬁles. Furthermore, ﬁnding predictive
genetic biomarkers could enable identiﬁcation of patients who
should be treated with neuroprotective agents (when they are
available) and/or be treated with reduced paclitaxel doses or
switched to nonneuropathic treatments.
In attempts to identify genes relevant to CIPN, several genome-
wide association studies (GWAS) have been conducted with the
identiﬁcation of SNP in FGD4 (9), EPHA5, and XKR4 (10)
associated with the risk of paclitaxel-induced sensory peripheral
neuropathy. Because it is challenging to replicate large, well-
controlled clinical trials to evaluate pharmacogenomics markers
of toxicity (11, 12), we developed an integrative approach com-
bining clinical studies and cell-based models enabling variant
identiﬁcation and followed with functional validation of the
ﬁndings to help elucidate underlying mechanisms and pathways
(13). Thismethod has found utility for paclitaxel-induced periph-
eral neuropathy in individuals of European descent and capeci-
tabine-induced hand-foot syndrome (14, 15).
Although paclitaxel is used globally, large clinical GWAS stud-
ies of paclitaxel-induced sensory peripheral neuropathy have
been performed primarily in European patients (9, 10, 14, 16).
However, pharmacoethnicity has been recognized as an impor-
tant factor in chemotherapeutic response and toxicity (17). In this
report, we compare genetic variants identiﬁed in a GWAS of
sensitivity of lymphoblastoid cell lines derived from individuals
of Asian, European, and African ancestry to variants identiﬁed in
an Asian patient GWAS of paclitaxel neuropathy. In addition to
analyzing SNPs, we identiﬁed signiﬁcant genes through expres-
sion quantitative trait loci (eQTL) data (18) and functionally
validate a target gene using human-induced pluripotent stem cell
(iPSC)-derived neurons.
Materials and Methods
Cytotoxicity assays
HapMap lymphoblastoid cell lines (LCL) derived from Japa-
nese individuals residing in Tokyo, Japan (HAPMAPPT02/05, JPT,
n ¼ 57) and a set derived from Han Chinese residing in Beijing,
China (HAPMAPPT02/05, CHB, n ¼ 59), purchased from the
Coriell Cell Repositories (Camden), were treated with increasing
concentrations (0, 6.25, 12.5, 25, 50, and 100nM) of paclitaxel
(Sigma-Aldrich, St. Louis, MO, USA). Cytotoxicity was determin-
ed using an AlamarBlue (Invitrogen, Life Technologies Inc.)
cellular growth inhibition assay as described previously (19).
Mean area under the paclitaxel concentration-cell survival per-
centage curve (AUC) was determined by at least six replicates
from two independent experiments and used as the phenotype in
the GWAS. AUC values for each cell line were log2-transformed
before statistical analysis to form an approximately normal dis-
tribution. Paclitaxel cytotoxicity data of CEU (n ¼ 77), YRI
(n ¼ 87), and ASW (n ¼ 83) are previously published (19).
For each population, a linear regression was calculated to deter-
mine the correlation between the AUC for each replicate; the
correlation for CEU, YRI, ASW, CHB, and JPT was 0.83, 0.86,
0.81, 0.83, and 0.82, respectively.
Authentication of cell lines
The PAAR Cell Core routinely checks the identity of LCLs by
genotyping 47 informative SNPs included in the Sequenom
iPLEX Sample ID Plus Panel. Using the DNeasy Blood and
Tissue Kit (Qiagen), DNA was extracted from each sample.
Genotyping was performed following the iPLEX Pro applica-
tion guide. The iPLEX Pro reaction products were dispensed
onto a 384-sample SpectroCHIP and run on a Sequenom
MassARRAY system at The University of Chicago DNA Sequenc-
ing and Genotyping Facility. Genotypes passed quality control
(formed clear genotype clusters) for 46 of 47 SNPs and all
46 genotypes matched the known HapMap (http://hapmap.
ncbi.nlm.nih.gov/) genotypes for all samples. Twenty-four of
116 LCLs were randomly chosen from this study and all passed
quality control.
LCL genome-wide association studies
A GWAS of paclitaxel-induced cytotoxicity was conducted by
combining the JPT and CHB (Asian population: ASN). Phased
genotype data of the 186 ASN cell lines sequenced in the 1000
Genomes Project phase I version 3 (20) were downloaded from
the BEAGLE website (http://faculty.washington.edu/browning/
beagle/beagle.html). An additional 15 ASN samples genotyped in
HapMap r28 were imputed to 1000 Genomes using BEAGLE
version 3.3.2 (21). Phased genotype data were also downloaded
for the 85 CEU and 88 YRI sequenced in the 1000 Genomes
Project and used to impute the additional 93 CEU and 90 YRI
samples genotyped in HapMap r28 with BEAGLE, which con-
siders the relatedness of the trios in the imputation. Within
each population, approximately 4.6 million SNPs [imputation
R2 > 0.8, population minor allele frequency (MAF) > 0.05, and
in Hardy–Weinberg equilibrium (P > 1  106)] were tested for
association with paclitaxel cytotoxicity using the linear mixed
model Wald test, which accounts for the genetic relatedness of
individuals, implemented in GEMMA version 0.94 (22).
Patient samples and GWAS
Germline DNA of 183 cancer patients treated with mono-
therapy paclitaxel stored in Biobank Japan (University of
Tokyo, Tokyo, Japan) were genotyped using Illumina Omni-
Express BeadChip that contained 733,202 SNPs (23). Of
them, 24 patients experienced either grade 2 or higher
Translational Relevance
Chemotherapy-induced peripheral neuropathy (CIPN)
causes a signiﬁcant symptom burden because many patients
that undergo adjuvant treatment are long-term survivors.
Moreover, CIPN can lead to dose reduction of the chemo-
therapeutic agent or possible cessation of treatment. This
may have an adverse impact on cancer treatment and disease
outcomes. In this study, we have used a genome-wide
approach in a clinical and preclinical setting to identify
genetic variants associated with peripheral neuropathy in
Asians. The ﬁndings can be used in a clinical setting to dose
reduce patients at risk or alter therapy to avoid this devas-
tating side effect. In addition, an improved understanding of
the pathophysiology of paclitaxel-induced neuropathy in
and across populations will assist in the development of
future neuroprotective agents and in the design of novel
therapies with improved toxicity proﬁles.
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paclitaxel-induced sensory peripheral neuropathy (PIPN), 121
patients revealed no neuropathy, and the remaining 38 indi-
viduals had grade 1 neuropathy. For GWAS, we used 24
patients who developed  grade 2 PIPN (cases), and compared
them with 121 patients who did not show neuropathy (con-
trols). The patient characteristics are described in Supplemen-
tary Table S1. The grade of toxicity was classiﬁed in accordance
with the US National Cancer Institute's Common Toxicity
Criteria version 2.0. All participants provided written informed
consent. This project was approved by the Institutional Review
Board in the Institute of Medical Science, the University of
Tokyo, and RIKEN Center for Genomic Medicine. Sample
quality control was carried out by methods, including identi-
ty-by-state to evaluate cryptic relatedness for each sample, and
population stratiﬁcation by the use of principal component
(PC) analysis to exclude genetically heterogeneous samples
from further analysis. Then, our standard SNP quality control
was carried out by excluding SNPs deviating from the Hardy–
Weinberg equilibrium (P  106), nonpolymorphic SNPs,
SNPs with a call rate of <0.99, and those on the X chromo-
some. We performed a genome-wide case/control allelic asso-
ciation study using the Fisher exact test.
LCL/patient comparison
We used the SCAN database to determine which of the top
SNPs signiﬁcantly associated with paclitaxel-induced cyto-
toxicity in ASN (P < 106) were located in or near (within
2 kb) gene transcripts (24, 25). We also used the eQTL Browser
(http://eqtl.uchicago.edu/Home.html) and GTEx Portal
(http://www.gtexportal.org/home/) to detect whether SNPs
genotyped in 1000 Genomes were eQTLs in LCLs and other
tissues. The previous genomic studies using LCLs showed that
Japanese and Han Chinese have similar genetic structure, but
cluster separately from European and African-American indi-
viduals in PCs analysis (26). We used Sherlock, the computa-
tional algorithm that matches patterns of GWAS results with
independent eQTL data to detect signiﬁcant genes associated
with the cytotoxicity and neuropathy phenotypes (18). We used
the public HapMap CEU eQTL dataset (27) contained in
Sherlock for gene association testing. Among the genes associ-
ated with each phenotype (P < 0.05) through Sherlock (18), the
LCL/patient overlap genes were prioritized for functional anal-
ysis. Results were also compared with the published clinical
GWAS of 855 genetic Europeans with breast cancer from
CALGB40101, in which a dose-to-event analysis was conducted
with an event deﬁned as paclitaxel-induced sensory peripheral
neuropathy  grade 2 (9).
Functional studies in iPSC-derived neurons
Human iPSC-derived cortical neurons, termed iCell Neurons
(Cellular Dynamics International), were used for functional val-
idation of the candidate genes. These cells have been previously
used to model chemotherapy-induced neuropathy (28, 29).
RNA-Seq. RNA isolation from iPSC-derived cortical neurons
was performed after removal of media and addition of 50 mL
Qiazol per well plate for 5 minutes at room temperature to lyse
cells. After vigorously pipetting each well several times, samples
were collected and stored for further processing at 70C. RNA
was puriﬁed using the Ambion RNA protocol (15596026.PPS),
only substituting Qiazol as the lysing reagent after consulting
with the company. The ﬁnal pellets were resuspended in 50 mL
RNAase-free water dissolved at 55C for 10 minutes, aliquoted
and stored at 70C. Nucleic acids quantiﬁcation was per-
formed using the Qubit dye for RNA kits (Molecular Probes,
Life Technologies), as per the manufacturer's speciﬁcations.
RNA (1 mg) from each time point was submitted to the Uni-
versity of Chicago Genomics Core. RNA quality was checked on
the Agilent Bio-analyzer 2100. RNA-SEQ libraries were gener-
ated in the core using Illumina RS-122-2101 TruSeq Stranded
mRNA LT Libraries and the ﬁnal libraries checked again on
the Agilent bio-analyzer 2100, which was followed by sequenc-
ing on the Illumina HiSeq2500. The raw sequencing reads
were processed and analyzed using the RNA-Seq pipeline in
the Galaxy Project (30). Brieﬂy, the raw reads were mapped to
the human genome reference (hg19) using TopHat2 (version
2.06; ref. 31), which aligns RNA-Seq reads to the human
genomes using the ultra high-throughput short read aligner
Bowtie2 (32). Cufﬂinks (version 0.0.7; ref. 33) was then used
to quantify and quantile normalize the expression levels of the
assembled transcripts.
siRNA knockdown studies. iCell Neurons (1.33 104)were seeded
with 3.3 mg/mL laminin (Sigma-Aldrich) in iCell Neuron com-
plete maintenance media onto poly–D-lysine coated 96-well
Greiner Bio-One plates (Monroe) according to the manufacture's
recommendations. Dharmacon Accell technology (GE Dharma-
con) was applied at 4 hours after plating using 1 mmol/L each
human siAIPL1, siPTPMT1, siBCR, or siDDX54 SMARTpool or the
nontargeting control (NTC). Twenty-four hours later cells were
either collected for real-time reverse transcription PCR (RT-PCR)
or an exchange of transfection media with paclitaxel at a dose
range of 0.001 to 10 mmol/L or 0.17% DMSO vehicle control.
After 24 or 48 hours, the drug was removed and cells were stained
with 1 mg/mL Hoechst 33342 (Sigma-Aldrich) and 2 mg/mL
Calcein AM in dPBS (Molecular Probes, Life Technologies Inc.).
Image analysis was performed on the ImageXpressMicro imaging
system (Molecular Devices, LLC) at the University of Chicago
Cellular Screening Center. Individual cell measurements of neur-
ite outgrowth, including mean/median/maximum process
length, total neurite outgrowth (sum of the length of all process-
es), number of processes, number of branches, cell body area,
mean outgrowth intensity and straightness were analyzed using
theMetaXpress software Neurite Outgrowth ApplicationModule.
Each experiment was replicated three times and the difference in
the relative neurite outgrowth for each siRNA treatment was
compared with NTC and tested for signiﬁcance by two-way
ANOVA analysis.
Cells for RT-PCR from 2 wells for each experiment were
collected at 24 and 48 hours posttransfection using Cells
to CT (Life Technologies) as recommended by the manu-
facturer. Two independent reverse transcription reactions were
performed, and the efﬁciency of knockdown for AIPL1
(Hs04185077_m1), PTPMT1 (Hs00378514_m1), BCR
(Hs01036532_m1), or DDX54 (Hs_00225320_m1; Life Tech-
nologies) for triplicate wells was determined using TaqMan
fast chemistry on the Viia7 PCR machine (Life Technologies).
A comparative DDCt analysis was used to determine the per-
centage knockdown of each gene by comparing the Ct dif-
ference relative with the beta-2-microglobulin control
(NM_004048.2) and normalizing to NTC.
Asian-Speciﬁc Target Genes in Paclitaxel-Induced Neuropathy
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Results
Paclitaxel-induced cytotoxicity in LCLs
HapMap LCLs were treated with increasing concentrations of
paclitaxel and cellular growth inhibition was measured. The log2
-transformed area under the survival curve (AUC) was used as the
paclitaxel-induced cytotoxicity phenotype. To evaluate ethnic
differences in mean log2 AUC of paclitaxel, we compared results
from LCLs derived from the Asian populations (JPT, n¼ 57; CHB,
n ¼ 59) with our previous data of three other HapMap LCL
populations (CEU, n ¼ 77; YRI, n ¼ 87; ASW, n ¼ 83; ref. 19).
The paclitaxel-induced log2-transformed cytotoxicity phenotype
showed normal distributions in each population. Figure 1 illus-
trates the paclitaxel-induced cytotoxicity among 5 populations
with no statistical differences among the populations observed.
Genome-wide association study in Asian LCLs
Figure 2 illustrates the Manhattan plot of paclitaxel-induced
cytotoxicity in LCLs derived from the Asian populations (JPT and
CHB). Therewere 248 SNPs associatedwith paclitaxel cytotoxicity
in the ASN population at a suggestive signiﬁcance of P < 105;
however, among themonly one SNP (rs56763443) and two SNPs
(rs8049617 and rs7598550) were signiﬁcant in the CEU and YRI
GWAS results at P < 0.05, respectively. Three of the most signif-
icant six SNPs in the ASNGWASof paclitaxel-induced cytotoxicity
were located near (within 2 kb) gene AIPL1 (aryl-hydrocarbon-
interacting protein-like 1). The three AIPL1 SNPs are in perfect
LD (r2 ¼ 1, D0 ¼ 1 in ASN), and thus represent one signal. We
evaluated whether any of these six SNPs were expression quan-
titative trait loci eQTLs with r2  0.8 in two distinct databases,
University ofChicagodatabase (http://eqtl.uchicago.edu/cgi-bin/
gbrowse/eqtl/) and GTEx Portal (http://www.gtexportal.org);
however, they were not eQTLs in any tissues listed (generic
genome browser version 1.68). We also downloaded the expres-
sion data collected from ASN LCLs in Stranger and colleagues
(34). We found no relationship between AIPL1 expression and
paclitaxel cytotoxicity (n ¼ 88, b ¼ 0.012, P ¼ 0.66) or AIPL1
expression and rs3892315 genotype (n ¼ 90, b ¼ 0.009, P ¼
0.52). Table 1 illustrates these three SNPs trending toward sig-
niﬁcance in LCLs derived from individuals of Northern/Western
Europe (CEU; P < 0.065–0.078), but there was no signiﬁcance
in African LCLs (YRI; P ¼ 0.305–0.355). Thus, the genetic vari-
ation near AIPL1 may contribute to paclitaxel-induced cyto-
toxicity particularly in Asians. Supplementary Table S2 lists 28
SNPs in or near AIPL1 and their association with sensory neu-
ropathy in Asian patients; one SNP (rs7214517) has a P value of
0.028. The three LCL SNPs (rs56763443, rs8049617, and
rs7598550) were not genotyped in the Asian study.
Functional validation of AIPL1 using human iPSC-derived
neurons
The effects of AIPL1 expression on paclitaxel-induced neuro-
toxicity was assessed in neurons derived from iPSCs. To evaluate
the effects of low AIPL1, expression on paclitaxel-induced neu-
rotoxicity, we modulated the gene in neurons through transient
siRNA transfection and veriﬁed with quantitative PCR (qPCR), a
reduction of expression in AIPL1 to 62% and 14% relative to
control at 24 and 48 hours posttransfection relative to NTC
(Fig. 3A). The modulation of expression of AIPL1 resulted in
increased resistance of neurons to paclitaxel at 48 hours using
two-way ANOVA analysis, as measured by signiﬁcant increase in
relative total outgrowth (Fig. 3B; P¼ 0.017), mean process length
(Fig. 3C; P ¼ 0.008), and relative number of processes (Fig. 3D;
P ¼ 0.029). Median process length (P ¼ 0.005), max process
length (P ¼ 0.011), phenotypes related to mean process length
andmean outgrowth intensity, a phenotype related to thickening
of the neurite outgrowths (P ¼ 0.0065) was also signiﬁcantly
Figure 1.
Cellular sensitivity to paclitaxel in 363 HapMap LCLs. LCLs from different
world populations (JPT, n¼ 57; CHB, n¼ 59; CEU, n ¼ 77; YRI, n¼ 87; ASW,
n ¼ 83) were phenotyped for the cellular growth inhibitory effects of
paclitaxel. The cytotoxicity phenotype is log2-transformed mean area under
the paclitaxel concentration-cell survival percentage curve (AUC). There
were no statistically signiﬁcant differences among the 5 populations.
Figure 2.
Asian LCL GWAS results. Paclitaxel-
induced cytotoxicity in Asian LCLs.
Top line in the Manhattan plot is at the
genome-wide signiﬁcance threshold
of P ¼ 5  108 and the bottom line is
at the suggestive signiﬁcance
threshold of P¼ 105. Q–Q plots show
some signal above the expected P
values (black lines represent the
expected 95% conﬁdence intervals) in
the LCL GWAS.
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Figure 3.
Decreased AIPL1 expression reduces
sensitivity of human iPSC-derived
neurons to paclitaxel. A, relative AIPL1
expression 24 to 48 hours
posttransfection normalized to NTC.
Neurite outgrowth phenotypes
measured following 48 hours
paclitaxel exposure (0.001–10
mmol/L) were tested for differences
between siAIPL1 and NTC by two-way
ANOVA, including relative total
neurite outgrowth (P ¼ 0.017; B),
relative mean process length (P ¼
0.008; C), and relative number of
processes (P ¼ 0.029; D). Error bars,
SEM from three experiments of>2,000
cells per dose. E, representative high-
content images comparing human
iPSC-derived neurons upon siRNA
knockdown ofAIPL1 and NTC 48 hours
after treatment with 0.01 mol/L
paclitaxel. Images taken at 10
magniﬁcation; scale bar, 100 mm.
Table 1. SNPs signiﬁcantly associated with paclitaxel-induced cytotoxicity in Asian LCLs (P < 106) and their level of signiﬁcance in CEU LCLs and YRI LCLs
ASN CEU YRI Host gene
SNP Beta P MAF Beta P MAF Beta P MAF
rs11595500 0.212 4.13E08 0.167 0.036 0.463 0.346 0.171 0.149 0.058 NA
rs264124 0.146 6.95E07 0.343 0.020 0.694 0.463 — — — NA
rs3892315 0.207 8.72E07 0.134 0.151 0.065 0.113 0.047 0.353 0.321 AIPL1
rs11651916 0.207 8.75E07 0.134 0.144 0.078 0.113 0.050 0.307 0.317 AIPL1
rs3892316 0.206 9.23E07 0.137 0.151 0.066 0.113 0.047 0.355 0.321 AIPL1
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different (data not shown). Figure 3E illustrates morphologic
changes for NTC- and siAIPL1-treated cells for neurite outgrowth
following 48 hours paclitaxel treatment of iPSC-derived neurons
by high-content imaging.
GWAS in patient samples of paclitaxel-induced neuropathy
We performed GWAS of paclitaxel-induced neuropathy in 183
Asian cancer patients (Fig. 4A). We identiﬁed four SNPs above a
suggestive threshold of P < 105 and no genome wide signiﬁcant
SNPs at P ¼ 5  108. Gene-based tests are commonly used
following traditional SNP-based analysis because they reduce
multiple testing andprovide genes as opposed to SNPs. Therefore,
we evaluated LCL Asian GWAS (Fig. 2), Asian cancer patient data
(Fig. 4A), and GWAS data from CALGB40101, a study of 855
Europeans evaluated for paclitaxel-induced neuropathy (9) using
Sherlock, a program that enables gene-based sorting of targets by
scoring alignment of genetic signatures of eQTLs and the pheno-
type (18). Comparison of results from Asian LCL cytotoxicity and
Asian patient neuropathy at P < 0.05, had 32 overlap genes
(Fig. 4B; Supplementary Table S3); comparison of Asian LCL
cytotoxicity and European patient neuropathy at P < 0.05 had
37 overlap genes (Fig. 4B, Supplementary Table S4) and compar-
ison of Asian and European patient GWAS cohorts at P < 0.05 had
10 overlap genes (Fig. 4B; Supplementary Table S5). Interestingly,
PTPMT1 (protein tyrosine phosphatase, mitochondrial 1) over-
lapped all three analyses: Asian LCL cytotoxicity, Asian patient
neuropathy, and European patient neuropathy at P < 0.05.
Although we modulated gene expression of PTPMT1 in iCell
neurons, resulting in 77% and 41% gene remaining after 24 and
48 hours, no signiﬁcant difference was found in any of the neurite
outgrowth phenotypes when compared with NTC (data not
shown), indicating that some mechanism distinct from levels of
gene expression may explain the role of PTPMT1 in paclitaxel-
induced peripheral neuropathy. Alternatively, the effect of gene
knockdown on other neuronal phenotypes such as electrical
activity would not be captured in this system that is focused on
morphologic changes.
Functional validation of BCR and DDX54 using human
iPSC-derived neurons
To prioritize the 32 Asian speciﬁc genes (Supplementary
Table S3), we evaluated both their gene level expression in
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iPSC-derived neurons (using RNA-Seq) and published literature
using PubMed search terms: Gene name and CIPN or neuropathy
or neurons done 2/2015 (Supplementary Fig. S6). Breakpoint
cluster region (Bcr) protein, highly expressed in iPSC-derived
neurons, is enriched in neurons and involved in neural activities,
and therefore was chosen for further studies (35–37). We found
that a change in expression to 62% and 67% at 24 and 48 hours
compared with NTC (Fig. 5A), resulting in a decrease in the
relative total outgrowth (P ¼ 0.0097), number of processes
(P ¼ 0.0298), max process length (P ¼ 0.0016), and number of
branches (P ¼ 0.0003; Fig. 5B–D) after treatment with pacli-
taxel in three independent experiments. Ddx54 protein has
been shown to play a critical role in central nervous system
myelination, presumably in myelin sheath formation after the
differentiation of oligodendrocytes (38). DDX54 (DEAD-box
RNA helicase) was modulated to 66% and 61% at 24 and
48 hours, but resulted in no signiﬁcant changes in any neurite
phenotypemeasured, including relative total outgrowth, number
of processes, max process length, and number of branches.
Discussion
A comparison of paclitaxel-induced cytotoxicity in LCLs
derived from patients of Asian, European, and African ancestry
demonstrates no difference in cellular sensitivity to paclitaxel.
Traditional GWAS reveals only a small fraction (3/248) SNPs
suggestively signiﬁcant in Asian LCLs for paclitaxel-induced
cytotoxicity are also signiﬁcant in either CEU or YRI LCLs with
the most signiﬁcant genetic variant associations unique within
populations. The top intragenic SNPs in the ASN GWAS of
paclitaxel-induced cytotoxicity were located near AIPL1 gene.
Upon knockdown of AIPL1 in human iPSC–derived neurons,
decreased sensitivity to paclitaxel as measured by neurite
outgrowth phenotypes was observed. Using a gene-based
approach, a gene identiﬁed as Asian speciﬁc (overlapped in
Asian LCLs and Asian clinical cohort of neuropathy) BCR
(breakpoint cluster region), was validated using iPSC-derived
neurons with knockdown corresponding to increased sensitiv-
ity to paclitaxel-induced damage to neurons. The same
approach identiﬁed PTPMT1 associated with paclitaxel-induced
cytotoxicity in Asian LCLs, as well as Asian and European
paclitaxel-induced peripheral neuropathy clinical cohorts. By
integrating gene-based analyses from clinical studies of pacli-
taxel-induced neuropathy in Asian and European patients with
LCL results, population speciﬁc, and across population target
genes were identiﬁed.
The HapMap LCLs are advantageous for evaluating pharma-
cogenomics of anticancer agents because these samples have
publicly available genotypes (39, 40) and sequencing data
(20) for GWAS. The samples also have gene expression (41),
miRNA (42), modiﬁed cytosine (43), and protein data (44)
that allow for the elucidation of potential function of the
genetic variants associated with pharmacologic pheno-
types. Our observation of a lack of population difference in
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paclitaxel-induced cytotoxicity is in contrast with population
differences observed for platinating agents (45) and antimeta-
bolites (46). In part, these population differences in drug
sensitivity may be explained by population differences in gene
expression (41). The role of gene expression in population
differences in chemotherapeutic cytotoxicity is supported by
the observation that pharmacologic SNPs for several different
chemotherapeutic agents (etoposide, daunorubicin, cisplatin,
carboplatin, cytarabine, and capecitabine) are enriched in
eQTLs or SNPs associated with gene expression (25). In con-
trast, pharmacologic SNPs associated with paclitaxel are not
enriched in eQTLs; however, enrichment in protein quantita-
tive trait loci has been observed (47). These differences may
be due to differences in mechanism of action of paclitaxel, a
microtubule stabilizer compared with the other cytotoxic
agents that target DNA.
In our Asian patient dataset, it appears that peripheral neurop-
athy is more common in females than males (males: 1 case/33
controls; females: 23 cases/88 controls); however, this gender
difference is likely confounded by differences in cumulative dose,
treatment schedule or age of the patients. Evidence suggests that
age, race, and comorbid conditions, such as diabetes, and cumu-
lative dose of drug administered may be associated with an
increased risk of developing neuropathy (48).
In efforts to decrease multiple tests and identify genes instead
of SNPs, we chose to utilize a gene-based approach to detect
clinically signiﬁcant genes with multiple trans eQTLs with
moderate associations, which cannot be identiﬁed from the
GWAS alone (18). We used Sherlock to compare genes signif-
icant in two patient studies of paclitaxel-induced neuropathy
(855 European and 183 Japanese) and the LCL data we gen-
erated in the Asian populations. According to the gene-based
test, 10 genes, including PTPMT1, were found to overlap
between Asians and Europeans along with hundreds of candi-
date gene associations that were unique to each population. At
this threshold, PTPMT1 was revealed as a common target of
paclitaxel-induced sensory peripheral neuropathy among
populations. PTPMT1 is anchored in the inner mitochondrial
membrane and is required for mitochondrial integrity and
oxidative respiration (49). Because its ablation increased apo-
ptosis in cancer cell lines and decreased differentiation and
proliferation, but not survival in embryonic stem cells, its
function may be cell-type speciﬁc in the regulation of cell
growth and survival (50). Thus, PTPMT1 in peripheral nerve
mitochondria may play a critical role in paclitaxel-induced
neurotoxicity across populations and is worth further studies.
Our data indicate that expression knockdown PTPMT1 in iPSC-
derived neurons did not alter sensitivity to paclitaxel as mea-
sured by morphologic changes in neuronal outgrowths; how-
ever, it is possible that the gene is important in electrical activity
or other measures of neuronal damage.
Through LCL GWAS of paclitaxel-induced cytotoxicity, SNPs
in AIPL1 were implicated as the most signiﬁcant intragenic
SNPs in the Asian LCLs. In evaluating SNPs within or close to
AIPL1, rs7214517 was associated with Asian patient peripheral
neuropathy (P¼ 0.028). AIPL1 expressed in rod and cone photo-
receptors has a critical role in cell viability, and gene defects in
AIPL1 cause heterogeneous degenerations of the human retina,
such as retinitis pigmentosa (51). Interestingly, this disease is
related to NARP syndrome (neuropathy, ataxia, and retinitis
pigmentosa), which is an inherited condition chieﬂy affecting
nervous systems due to mitochondrial DNA dysfunction in cre-
ating adenosine triphosphate (52). Its worldwide prevalence is
unknown and it remains unclear how this disruption in mito-
chondrial energyproduction leads tomuscleweakness, vision loss
and the other speciﬁc features of NARP syndrome. Kirschman and
colleagues (53) also found that transgenic expression of AIPL1
restored rod morphology and the rod-derived electroretinogram
response in Aipl/ mice, implicating a neuron component for
this gene. Mitochondrial dysfunction has been implicated as a
mechanism for neurotoxicity of paclitaxel (54) and our results
demonstrated that decreased expression of AIPL1 signiﬁcantly
decreased sensitivity of neurons to paclitaxel; hence, there could
be a cell-type–speciﬁc function of AIPL1 in a mitochondrial
component in peripheral neurons and AIPL1 could be a potential
therapeutic target of paclitaxel-induced sensory peripheral neu-
ropathy especially in Asians.
We identiﬁed a set of 32 Asian speciﬁc genes that overlapp-
ed in the Asian LCL and Asian patient datasets. One of those
genes, BCR, was functionally validated in the iPSC-derived
neuronal model with increased sensitivity of neurons to pac-
litaxel upon knockdown of the gene. Bcr has been shown in
rat PC12 cells to cooperate with Fes to activate Rho family
GTPases as part of a novel pathway regulating neurite exten-
sion (55). Furthermore, Huntington's-associated protein, 1A
interacts with Bcr on microtubules to regulate neuronal dif-
ferentiation (56). Increasingly, Bcr is emerging as an important
regulator of excitatory synapse receptor expression and devel-
opment. Our data indicate that BCR contributes to the pro-
tection of neurons from paclitaxel-induced damage as mea-
sured by several neuronal phenotypes, including total out-
growth of neurites.
Although CIPN is a common, potentially severe and dose-
limiting adverse effect of many commonly used cancer therapeu-
tics, including paclitaxel, there are no effective genetic markers or
treatment for this side effect (4, 7, 8). Therefore, to identify genetic
variants and genes associated with CIPN, several large clinical
GWAS have been conducted and revealed a few promising asso-
ciations (9, 10, 14). However, there are some considerable
issues in clinical GWAS of CIPN, including (i) lack of replication
studies; (ii) pharmacogenomics underlying ethnic speciﬁcity;
and (iii) lack of appropriate models to functionally validate
important GWAS results. Therefore, combining cell-based data
with multiple clinical genome-wide association studies, as done
in this study, is a way to identify the most promising genes.
Furthermore, we utilized a novel technology, human iPSC-
derived neurons for gene functional validation. The elucidation
of variants speciﬁc to the Asian population may be helpful in
developing personalized cancer treatments.
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